Search results for: Anti-ALDH3B2 Antibody
#35752946 
2022/06/26
To Up
Immunocastration in adult boars as a model for late-onset hypogonadism.
While immunocastration (IC) has been studied in male pre-pubertal pigs, data on older, sexually mature animals are limited. To understand the physiological effects of androgen deprivation in the late sexual development phase, we compared mature immunocastrated boar (MIC) boars (n = 19; average age = 480 days) to young male immunocastrated pigs (YIC) (n = 6; average age = 183 days) and young entire males (EMs) (n = 6; average age = 186 days) as positive and negative controls, respectively.Nina Batorek-LukaÄ, Kevin Kress, Marjeta Äandek-Potokar, Gregor Fazarinc, Martin Å krlep, Klavdija Poklukar, Raffael Wesoly, Volker Stefanski, Milka Vrecl
1822 related Products with: Immunocastration in adult boars as a model for late-onset hypogonadism.
18 kgs100 μg100 μg100 assays96 assays 100 assays900 tests24 tests1 kit1,000 tests
Related Pathways
#35752943 2022/06/25
To Up
Induction of a Cytokine Storm Involves Suppression of the Osteopontin-Dependent TH1 Response.
Cytokine release syndromes represent a severe turn in certain disease states, which may be caused by several infections, including those with the virus SARS-CoV-2. This inefficient, even harmful, immune response has been associated with a broad release of chemokines. Although a cellular (type I) immune reaction is efficacious against viral infections, we noted a type I deficit in the cytokine patterns produced by cytokine storms of all reported etiologies. Agents including lipopolysaccharide (LPS, bacterial), anti-CD3 (antibody) and a version of the prominent SARS-CoV-2 viral surface molecule, Spike Glycoprotein, were individually sufficient to induce IL-6 and multiple chemokines in mice. They failed to upregulate the TH1 inducer cytokine Osteopontin, and the pathophysiologic triggers actually suppressed the PMA-induced Osteopontin secretion from monocytic cells. Osteopontin administration partially reversed the chemokine elevation, more effectively so in a mouse strain with TH1 bias. Corroboration was obtained from the inverse correlation in the levels of IL-6 and Osteopontin in plasma samples from acute COVID-19 patients. We hypothesize that the inhibition of Osteopontin by SARS-CoV-2 Spike Glycoprotein or LPS represents an immune evasion mechanism employed by the pathogens of origin. The ensuing dysfunctional inflammatory response promotes a vicious cycle of amplification, resulting in a cytokine storm. This article is protected by copyright. All rights reserved.Gulimirerouzi Fnu, Kristin Hudock, Margaret Powers-Fletcher, Ruo-Pan Huang, Georg F Weber
2158 related Products with: Induction of a Cytokine Storm Involves Suppression of the Osteopontin-Dependent TH1 Response.
16 Arrays/Slide16 Arrays/Slide16 Arrays/Slide16-22 Sample Kit100ug Lyophilized4 Sample Kit2 Membrane supply4 Arrays/Slide1-8 Sample Kit100ug100ug Lyophilized8 Sample Kit
Related Pathways
#35752929 2022/06/25
To Up
Kidney transplant from hepatitis C viremic donors into aviremic recipients and risk for post-transplant BK and CMV infection.
kidney transplantation from HCV-viremic donors to uninfected recipients is associated with excellent short-term outcomes. However, HCV viremia might be associated with an increased risk for post-transplant viral complications.Reem Daloul, Kendra Schnelle, Lauren Von Stein, April Logan, Priyamvada Singh, Priya Yenebere, Todd Pesavento, Kenneth Washburn
2486 related Products with: Kidney transplant from hepatitis C viremic donors into aviremic recipients and risk for post-transplant BK and CMV infection.
25 mg10 mg2.5 mg1 mg100 mg25 mg10 mg50 mg25 mg10 mg500 mg
Related Pathways
-
No related Items
#35752827 2022/06/25
To Up
Exosomal tRF-Leu-AAG-001 derived from mast cell as a potential non-invasive diagnostic biomarker for endometriosis.
The diagnosis of endometriosis (EMs) is still based on laparoscopic observation. This study tries to verify whether exosomal tRNA-derived fragments (tRFs) in leucorrhea can be used as non-invasive diagnostic markers.Yingxue Li, Shuling Cui, Zemin Xu, Yanping Zhang, Tao Wu, Jing Zhang, Yichen Chen
2309 related Products with: Exosomal tRF-Leu-AAG-001 derived from mast cell as a potential non-invasive diagnostic biomarker for endometriosis.
1 kit1 kit1 kit1 kit1 kit10 plates100 Tests1000 assays96 assays
Related Pathways
#35752760 2022/06/25
To Up
ISM1 suppresses LPS-induced acute lung injury and post-injury lung fibrosis in mice.
Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) are clinical syndromes characterized by acute lung inflammation, pulmonary edema and hypoxemia, with up to 50% mortality rate without effective pharmacological therapy. Following the acute inflammation, repair and remodeling occurs which in some cases resulting in lung fibrosis. The pathophysiology of ALI/ARDS remains incompletely understood. Lipopolysaccharide (LPS)-induced ALI in mice have been widely used as a model to study human ALI/ARDS. Isthmin 1 (ISM1) is a secreted protein highly abundant in mouse lung. We have previously reported that upon intratracheal LPS instillation, ISM1 expression in the lung is further upregulated. Recently, we also reported that ISM1 is an anti-inflammatory protein in the lung with Ism1 mice presenting spontaneous chronic low-grade lung inflammation and obvious emphysema at young adult stage. However, what role ISM1 plays in ALI/ARDS and lung fibrosis remain unclear.Ngan Nguyen, Simin Xu, Terence Yin Weng Lam, Wupeng Liao, W S Fred Wong, Ruowen Ge
2634 related Products with: ISM1 suppresses LPS-induced acute lung injury and post-injury lung fibrosis in mice.
96T
Related Pathways
#35752711 2022/06/25
To Up
Ribonuclease 4 is associated with aggressiveness and progression of prostate cancer.
Prostate specific antigen screening has resulted in a decrease in prostate cancer-related deaths. However, it also has led to over-treatment affecting the quality of life of many patients. New biomarkers are needed to distinguish prostate cancer from benign prostate hyperplasia (BPH) and to predict aggressiveness of the disease. Here, we report that ribonuclease 4 (RNASE4) serves as such a biomarker as well as a therapeutic target. RNASE4 protein level in the plasma is elevated in prostate cancer patients and is positively correlated with disease stage, grade, and Gleason score. Plasma RNASE4 level can be used to predict biopsy outcome and to enhance diagnosis accuracy. RNASE4 protein in prostate cancer tissues is enhanced and can differentiate prostate cancer and BPH. RNASE4 stimulates prostate cancer cell proliferation, induces tumor angiogenesis, and activates receptor tyrosine kinase AXL as well as AKT and S6K. An RNASE4-specific monoclonal antibody inhibits the growth of xenograft human prostate cancer cell tumors in athymic mice.Nil Vanli, Jinghao Sheng, Shuping Li, Zhengping Xu, Guo-Fu Hu
1948 related Products with: Ribonuclease 4 is associated with aggressiveness and progression of prostate cancer.
1 G100ug Lyophilized100ug Lyophilized100ug LyophilizedEach100ug Lyophilized
Related Pathways
#35752708 2022/06/25
To Up
Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021.
A national point seroprevalence study of SARS-CoV-2 was conducted in Sweden in April-May 2021. In total, 2860 individuals 3 to 90 years old from a probability-based web panel were included. Results showed that an estimated 32.6% of the population in Sweden had detectable levels of antibodies, and among non-vaccinated 20.1% had detectable levels of antibodies. We tested for differences in seroprevalence between age groups and by sex and estimated seroprevalence among previously infected participants by time since reporting.Jessica Beser, Ilias Galanis, Theresa Enkirch, Sharon Kühlmann Berenzon, Edward van Straten, Jan Duracz, Marie Rapp, Katherina Zakikhany, Mikael Mansjö, Julia Wigren Byström, Mattias N E Forsell, Ramona Groenheit, Karin Tegmark Wisell, Andreas Bråve
2298 related Products with: Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021.
5mg5mg50 mg10 mg500 gm.500 mg200ul250ul 25 G20x50 ug250ul 25 G
Related Pathways
#35752654 2022/06/25
To Up
Profiling the neurovascular unit unveils detrimental effects of osteopontin on the blood-brain barrier in acute ischemic stroke.
Blood-brain barrier (BBB) dysfunction, characterized by degradation of BBB junctional proteins and increased permeability, is a crucial pathophysiological feature of acute ischemic stroke. Dysregulation of multiple neurovascular unit (NVU) cell types is involved in BBB breakdown in ischemic stroke that may be further aggravated by reperfusion therapy. Therefore, therapeutic co-targeting of dysregulated NVU cell types in acute ischemic stroke constitutes a promising strategy to preserve BBB function and improve clinical outcome. However, methods for simultaneous isolation of multiple NVU cell types from the same diseased central nervous system (CNS) tissue, crucial for the identification of therapeutic targets in dysregulated NVU cells, are lacking. Here, we present the EPAM-ia method, that facilitates simultaneous isolation and analysis of the major NVU cell types (endothelial cells, pericytes, astrocytes and microglia) for the identification of therapeutic targets in dysregulated NVU cells to improve the BBB function. Applying this method, we obtained a high yield of pure NVU cells from murine ischemic brain tissue, and generated a valuable NVU transcriptome database ( https://bioinformatics.mpi-bn.mpg.de/SGD_Stroke ). Dissection of the NVU transcriptome revealed Spp1, encoding for osteopontin, to be highly upregulated in all NVU cells 24 h after ischemic stroke. Upregulation of osteopontin was confirmed in stroke patients by immunostaining, which was comparable with that in mice. Therapeutic targeting by subcutaneous injection of an anti-osteopontin antibody post-ischemic stroke in mice resulted in neutralization of osteopontin expression in the NVU cell types investigated. Apart from attenuated glial activation, osteopontin neutralization was associated with BBB preservation along with decreased brain edema and reduced risk for hemorrhagic transformation, resulting in improved neurological outcome and survival. This was supported by BBB-impairing effects of osteopontin in vitro. The clinical significance of these findings is that anti-osteopontin antibody therapy might augment current approved reperfusion therapies in acute ischemic stroke by minimizing deleterious effects of ischemia-induced BBB disruption.Daniel Spitzer, Sylvaine Guérit, Tim Puetz, Maryam I Khel, Moritz Armbrust, Maika Dunst, Jadranka Macas, Jenny Zinke, Gayatri Devraj, Xiaoxiong Jia, Florian Croll, Kathleen Sommer, Katharina Filipski, Thomas M Freiman, Mario Looso, Stefan Günther, Mariangela Di Tacchio, Karl-Heinz Plate, Yvonne Reiss, Stefan Liebner, Patrick N Harter, Kavi Devraj
2190 related Products with: Profiling the neurovascular unit unveils detrimental effects of osteopontin on the blood-brain barrier in acute ischemic stroke.
200 units500 Units500 Units500 Units1
Related Pathways
#35752484 2022/06/22
To Up
[Contribution of antiphosphatidylserine/prothrombin (anti-PS/PT) antibody detection in the diagnosis and management of antiphospholipid syndrome (APS)].
Antiphospholipid syndrome (APS) is an autoimmune disease and one of the most common causes of acquired thrombophilia. It is characterised by the occurrence of thrombotic or obstetric events associated with the presence of persistent antiphospholipid antibodies. The diagnosis can be challenging, particularly because some biological tests can be disturbed by anticoagulant treatment or inflammation. In the recent years, new antiphospholipid antibodies, including anti-phosphatidylserine/prothrombin antibodies (anti-PS/PT), have emerged but their clinical significance and causality remain uncertain. Biologically, several studies have found a strong correlation between the presence of lupus anticoagulant (LA) and anti-PS/PT antibodies. Clinically, the presence of anti-PS/PT antibodies is associated with an increased risk of thrombosis and obstetric complications. There is also an association with thrombocytopenia, suggesting that the presence of anti-PS/PT antibodies may be associated with more severe clinical APS. Among seronegative APS patients, 6-17% of patients are positive for anti-PS/PT antibodies. This might influence the therapeutic management of patients. This article aims to provide an update on contribution of anti-PS/PT antibodies detection for the diagnosis and management of APS.A Delarue, M-A Dragon-Durey, L Darnige
1529 related Products with: [Contribution of antiphosphatidylserine/prothrombin (anti-PS/PT) antibody detection in the diagnosis and management of antiphospholipid syndrome (APS)].
100ug100ug100ug Lyophilized100ug100ug100ug Lyophilized100ug Lyophilized100ug100ug Lyophilized100ug Lyophilized
Related Pathways
#35752438 2022/06/22
To Up
Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment.
The tumor microenvironment is mainly flooded with immunosuppressive cells and inhibitory cytokines, resulting in the inability of effective immune cells to infiltrate and recognize tumors and even the loss of anti-cancer ability.Tung-Yun Wu, Michael Chen, I-Chung Chen, Yi-Jou Chen, Che-Yi Chen, Chang-Hung Wang, Jing-Jy Cheng, Kunal Nepali, Kuo-Hsiang Chuang, Jing-Ping Liou